Skip to Content
Merck
CN
All Photos(1)

Documents

Y0000443

Flunixin meglumine

European Pharmacopoeia (EP) Reference Standard

Sign Into View Organizational & Contract Pricing
All Photos(1)
Synonym(s):
2-[[2-Methyl-3-(trifluoromethyl)phenyl]amino]-3-pyridinecarboxylic acid meglumine salt, Banamine
Empirical Formula (Hill Notation):
C14H11F3N2O2·C7H17NO5
CAS Number:
42461-84-7
Molecular Weight:
491.46
MDL number:
MFCD01725419
UNSPSC Code:
41116107
PubChem Substance ID:
329830960
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

flunixin

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.Cc1c(Nc2ncccc2C(O)=O)cccc1C(F)(F)F

InChI

1S/C14H11F3N2O2.C7H17NO5/c1-8-10(14(15,16)17)5-2-6-11(8)19-12-9(13(20)21)4-3-7-18-12;1-8-2-4(10)6(12)7(13)5(11)3-9/h2-7H,1H3,(H,18,19)(H,20,21);4-13H,2-3H2,1H3/t;4-,5+,6+,7+/m.0/s1

InChI key

MGCCHNLNRBULBU-WZTVWXICSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Flunixin meglumine (IC50 = 1 nM) can be used as a drug for animals for the management of intestinal ischaemia, colic, and endotoxemia in horses.

Biochem/physiol Actions

COX1, COX2 and PLA2 inhibitor non-narcotic analgesic, anti-pyretic, anti-inflammatory.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

Y0000445

Flunixin impurity C, European Pharmacopoeia (EP) Reference Standard

Y0000444

Flunixin impurity B, European Pharmacopoeia (EP) Reference Standard

1274607

Flunixin meglumine, United States Pharmacopeia (USP) Reference Standard

1274631

Flunixin Related Compound C, United States Pharmacopeia (USP) Reference Standard

1274630

Flunixin Related Compound B, United States Pharmacopeia (USP) Reference Standard

1274629

Flunixin Related Compound A, United States Pharmacopeia (USP) Reference Standard

PHR2305

Flunixin Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2413

Flunixin Related Compound C, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2823

Flunixin Related Compound B, Pharmaceutical Secondary Standard; Certified Reference Material

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H315,H319,H335

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Target Organs

Respiratory system

WGK

WGK 3

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

A J Morton et al.
Equine veterinary journal. Supplement, (39)(39), 112-116 (2011-08-04)
The effects of prostaglandins and nonsteroidal anti-inflammatory drugs (NSAIDs) on repair of equine intestinal mucosa are important since most horses with gastrointestinal diseases are routinely treated with NSAIDs, such as flunixin meglumine (FM), and these drugs can be toxic to
J F Marshall et al.
Equine veterinary journal. Supplement, (39)(39), 106-111 (2011-08-04)
Flunixin meglumine is used for treatment of equine colic despite evidence of inhibited recovery of mucosal barrier function following small intestinal ischaemic injury. This study aimed to characterise an alternative treatment (AHI-805) for abdominal pain in the horse. To determine
J Cuervo-Arango et al.
Theriogenology, 77(3), 514-524 (2011-10-01)
The development of hemorrhagic anovulatory follicles (HAF) involves luteinization and hemorrhage of the follicle. This is observed on ultrasound as an increase in the echogenicity of the granulosa layer and formation of echoic particles in the antrum. The inhibition of
Pharmacokinetic interactions of flunixin meglumine and doxycycline in broiler chickens.
F Yang et al.
Journal of veterinary pharmacology and therapeutics, 36(1), 85-88 (2012-02-02)
Mitchel R Stacy et al.
The Journal of thoracic and cardiovascular surgery, 148(5), 2227-2233 (2014-06-24)
The clinical translation of tissue-engineered vascular grafts has been demonstrated in children. The remodeling of biodegradable, cell-seeded scaffolds to functional neovessels has been partially attributed to matrix metalloproteinases. Noninvasive assessment of matrix metalloproteinase activity can indicate graft remodeling and elucidate
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service